Evidence map›Paper›PMID 36083411›Full record

ArticleCell biochemistry and biophysics2022

Role of a Disease-associated ST3Gal-4 in Non-small Cell Lung Cancer.

Praveen Singh, Archana Joon, Munmun Kumari, Tanya Singh, Amanjit Bal, Pratibha Maan, Sujata Ghosh

Abstract read
PubMed Publisher
In one paragraph

Article in Cell biochemistry and biophysics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Praveen SinghDepartment of Experimental Medicine and Biotechnology, PGIMER, Chandigarh, 160012, India.
Archana JoonDepartment of Experimental Medicine and Biotechnology, PGIMER, Chandigarh, 160012, India.
Munmun KumariDepartment of Experimental Medicine and Biotechnology, PGIMER, Chandigarh, 160012, India.
Tanya SinghDepartment of Experimental Medicine and Biotechnology, PGIMER, Chandigarh, 160012, India.
Amanjit BalDepartment of Histopathology, PGIMER, Chandigarh, 160012, India.
Pratibha MaanDepartment of Experimental Medicine and Biotechnology, PGIMER, Chandigarh, 160012, India.
Sujata GhoshDepartment of Experimental Medicine and Biotechnology, PGIMER, Chandigarh, 160012, India. sujataghosh12@gmail.com.ORCID http://orcid.org/0000-0002-8360-0508
Post Graduate Institute of Medical Education and Research · IN

Funding

pgimer 71/6-Edu-13/3245
6 · The paper itself

Abstract

Sialylation promotes tumorigenesis by affecting various cancer-related events, including apoptosis inhibition, cell growth, invasion, migration, metastasis, chemo-resistance, and immunomodulation in favor of tumor progression. An altered expression of sialyltransferase enzymes is responsible for synthesizing various tumor-associated sialylated structures. In the present study, our findings have revealed a significant up-regulation of ST3Gal-4 transcript in the two major subtypes of NSCLC cell lines [squamous cell carcinoma cell line (NCI-H520) and adenocarcinoma cell line (A549)]. Thus, the role of the ST3Gal-4 gene was assessed on cancer-associated signal transduction pathways in these cells in view of proliferation, invasion, and migration. ST3Gal-4 was silenced by transfection of both the cell lines with esi-ST3Gal-4-RNA, which RT-PCR and western immunoblotting confirmed. Silencing of ST3Gal-4 resulted in a decreased expression of MAL-I interacting membrane-HSP60, identified earlier as an α2,3-sialylated glycoprotein, thus pointing towards the possible role of ST3Gal-4 in its sialylation. The proliferation, invasion, and migration of both types of NSCLC cells were reduced significantly in the ST3Gal-4 silenced cells. Our findings were substantiated by the down-regulation of β-catenin and E-cadherin, a reduced expression of activated AKT1, ERK1/2, and NF-ƙB in these cells. We propose that ST3Gal-4 may be the disease-associated sialyltransferase involved in α2,3 sialylation of the membrane proteins, including HSP60 of the NSCLC cells. This may lead to the conformational alteration of these proteins, required for the activation of E-cadherin/β-catenin, AKT, and ERK/NF-ƙB mediated signal transduction pathways in these cells, resulting in their proliferation, invasion, and migration.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsSialyltransferasesbeta Cateninbeta-Galactoside alpha-2,3-SialyltransferaseCadherinsCell Line, TumorCell MovementCell ProliferationHumansNF-kappa BProto-Oncogene Proteins c-aktRNAbeta Cateninbeta-Galactoside alpha-2,3-SialyltransferaseCadherinsNF-kappa BProto-Oncogene Proteins c-aktRNASialyltransferasesST3GAL4 protein, humanNSCLCSialyltransferaseSignaling moleculesST3Gal-4

Identifiers

PMID36083411
OpenAlexW4295077801

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.